期刊文献+

胃转流术后血糖与胰升血糖素样肽-1改变的实验研究 被引量:1

Experimental study on the SD rats to observe the change of glucose and GLP-1 levels after gastric bypass
原文传递
导出
摘要 目的探讨胃转流手术(GBP)后糖代谢与胰升血糖素样肽-1(GLP-1)的变化规律。方法选取GK大鼠30只,随机分为5组,术后4周时检测OGTT,ELISA检测血浆总GLP-1的表达。结果与Ⅰ组术前相比,各组术后OGTT各时间点血糖水平均明显下降(P<0.05);与Ⅱ组术前相比,Ⅲ~Ⅴ组术后血糖水平差异无统计学意义(P>0.05);与Ⅰ组[空腹(42.7±4.9)pmol/L,餐后(47.5±7.9)pmol/L]相比,Ⅱ~Ⅴ组空腹和餐后30min血浆总GLP-1值上升(P<0.05);与Ⅱ组[空腹(54.0±6.5)pmol/L,餐后(75.1±13.8)pmol/L]相比,Ⅲ~Ⅴ组空腹和餐后30 min血浆总GLP-1值均呈上升趋势,餐后30min血浆总GLP-1表达明显上升(P分别为0.01、0.000、0.000);与Ⅲ组[空腹(54.0±6.5)pmol/L,餐后(75.1±13.8)pmol/L]相比,随着转流肠襻长度的增加,Ⅳ、Ⅴ组空腹和餐后30min血浆总GLP-1表达逐渐升高,Ⅴ组餐后30min血浆总GLP-1表达明显上升(P=0.01)。结论肠道GLP-1表达的最佳效应区域位于小肠中段,GBP对T2DM的治疗作用与术后血浆GLP-1水平上调相关,是手术治疗糖尿病的机制之一。 Objective To establish the stomach-preserving Roux-en-Y gastric bypass model in SD rats and investigate the changing laws of glucose metabolism and glucagon-like peptide-1(GLP-1) level after surgery.Methods Thirty SD rats were randomized into five groups: group I(sham operation),groupⅡ(traditional bypass),group Ⅲ(duodenum bypass),group Ⅳ(jejunum bypass),group Ⅴ(ileum bypass).OGTT and total plasma GLP-1 expression were evaluated before and 4 weeks after operation for observation.Results Compared with group I,the blood glucose level in the experimental groups dropped significantly at all OGTT time points after surgery.Compared with group Ⅱ,the change in blood glucose level in the group Ⅲ,Ⅳ,and Ⅴ was not statistically significant after surgery(P0.05).Compared with the total plasma GLP-1 expression in group I [fasting(42.7±4.9) pmol/L,after meal(47.5±7.9) pmol/L],the total plasma GLP-1 expression in group Ⅱ,Ⅲ,Ⅳ,and Ⅴ increased at fasting and 30 min after meal(P0.05).Comparing with the total plasma GLP-1 expression in group Ⅱ [fasting(54.0±6.5) pmol/L,after meal(75.1±13.8) pmol/L],the total plasma GLP-1 expression in group Ⅲ,Ⅳ,and Ⅴ increased at fasting and 30 min after meal,especially in 30 min after meal(P=0.01,0.000,and 0.000 respectively).Comparing with the total plasma GLP-1 expression in group Ⅲ [fasting(54.0±6.5) pmol/L,after meal(75.1±13.8) pmol/L],the total plasma GLP-1 expression in group Ⅳ and Ⅴ increased gradually at fasting and 30 min after meal owing to the increased length of intestinal loop,especially in group Ⅴ at 30 min after meal(P=0.01).Conclusion The effective section of GLP-1 expression in gut locates in the middle part of small intestine,and the remission effect of GBP on T2DM is associated with increased GLP-1 expression,being one of the mechanisms of operative treatment for diabetes.
出处 《中国糖尿病杂志》 CAS CSCD 北大核心 2013年第2期181-184,共4页 Chinese Journal of Diabetes
关键词 胃转流手术 糖尿病 2型 糖代谢 胰升糖素样肽-1 大鼠 Diabetes mellitus type 2 Gastric bypass surgery Glucagon-like peptide 1(GLP-1) Rats
  • 相关文献

参考文献2

二级参考文献13

  • 1李光伟,Step.,L.检测人群胰岛素敏感性的一项新指数[J].中华内科杂志,1993,32(10):656-660. 被引量:2125
  • 2Ballantyne GH, Wasielewski A, Saunders JK. The surgical treatment of type II diabetes mellitus: changes in HOMA insulin resistance in the first year following laparoscopic Roux-en-Y gastric bypass (LRYGB)and laparoscopic adjustable gastric banding (LAGB). Obes Surg, 2009,19 : 1297-1303.
  • 3Guidone C, Manco M, Valera-Mora E, et al. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes, 2006, 55:2025-2031.
  • 4Schauer PR, Burguera B, Ikramuddins, et al. Effect of laparoscopic Roux-En Y gastric bypass on type 2 diabetes mellitus. Ann Surg, 2003,238:467-485.
  • 5Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg, 1995, 222: 339-350.
  • 6Caterina G, Melania M, Elena VM, et al. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes, 2006,55: 2025-2031.
  • 7Mingrone G. Role of the incretin system in the remission of type 2 diabetes following bariatric surgery. Nutr Metab Cardiovasc Dis, 2008,18.-574-579.
  • 8Jia WP, Lu JX, Xiang KS,et al. Epidemiological study on obesity and its eomorbidities in urban Chinese older than 20 years of age in Shanghai, China. Obes Rev, 2002,3 : 157-165.
  • 9Ballantyne GH, Wasielewski A, Saunders .IK. The surgical treatment of type II diabetes mellitus: changes in HOMA Insulin resistance in the first year following laparoscopic Roux-en-Y gastric bypass (LRYGB) and laparoseopie adjustable gastric banding (LAGB). Obes Surg, 2009,19 : 1297-1303.
  • 10Guidone C, Manco M, Valera-Mora E, et al. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes, 2006, 55 :2025-2031.

共引文献35

同被引文献18

  • 1Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med ,2009,122 ( 3 ) :248 - 256.
  • 2Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obes Surg,2013,23 ( 4 ) :427 - 436.
  • 3Rubino F. Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis. Diabetes Care, 2008, 31 ( Suppl 2 ) : S290 - S296.
  • 4Partha B. Programmed disorders of beta-cell development andfunction as one cause for type 2 diabetes? The GK rat paradigm. Diabetes Metab Res Rev, 2005, 21:495 -504.
  • 5Mingrone G, Pananzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med, 2012,366 ( 17 ) : 1577 - 1585.
  • 6Dixon JB, Zimmet P, Alberti KG, et al. Bariatric surgery: an IDF statement for obese type 2 diabetes. Diabet Med, 2011,28 ( 6 ) : 628 - 642.
  • 7Laferrre B, Swerdlow N, Bawa B, et al. Rise of oxyntomodulin in response to oral glucose after gastric bypass surgery in patients with type 2 diabetes. J Clin Endocrinol Metab, 2010, 95 ( 8 ) : 4072 - 4076.
  • 8Dirksen C, Jorgensen NB, Bojsen-Moller KN, et al. Mechanisms of improved glyeaemic control after Roux-en-Y gastric bypass. Diabetologia ,2012,55 ( 7 ) : 1890 - 1901.
  • 9Stefater MA, Wilson-Perez HE, Chambers AP, et al. All bariatric surgeries are not created equal: insights from mechanistic comparisons. Endocr Rev ,2012,33 (4) :595 - 622.
  • 10Flatt PR. Effective surgical treatment of obesity may be mediated by ablation of the lipogenic gut hormone gastric inhibitory polypeptide (GIP) : evidence and clinical opportunity for development of new obesity-diabetes drugs. Diab Vasc Dis Res,2007,4(2) :151 -153.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部